EUCTR2004-003435-31-BE进行中（未招募）不适用
A Phase III Study of the Efficacy and Safety of Alzhemed™ as Add-on Therapy in Mild to Moderate Alzheimer's Disease Patients.
eurochem Inc.0 个研究点目标入组 930 人开始时间: 2005年8月29日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 930
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Potential participants must be 50 years of age or older.
- •2) Female subjects must be of non-childbearing potential (i.e. surgically sterilized or at least 2 years post-menopausal). All subjects must agree to ensure that appropriate contraceptive measures will be taken during the course of the study.
- •3) Diagnosis of dementia based on the Diagnostic and Statistical Manual, 4th edition
- •(DSM-IV) criteria
- •4) Diagnosis of probable AD based on the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA criteria)
- •5) Severity of dementia of mild to moderate degree as reflected by a score of 16-26 (inclusive) on the MMSE performed at the screening visit.
- •6) The potential participant must be living in a community with a reliable caregiver that will attend each clinic visit, complete required evaluations, supervise and ensure that all doses of medication are administered appropriately during the entire study. A reliable caregiver is an individual who has daily contacts (including visits and/or phone calls) with the participant. For consistency, it is recommended to have the same caregiver accompanying the participant at each visit. Participants living in assisted living facilities may be included in the study as long as the study medication intake is supervised and the participant has a reliable caregiver. Due to the length of this study, it is highly recommended to identify other potential caregivers during the screening evaluation.
- •7) The potential participant must be able to perform the required psychometric tests and evaluations. Visual and auditory acuity (with glasses or hearing aid if required) must be sufficient to complete the protocol-specified procedures.
- •8) The potential participant must have a Geriatric Depression Scale (GDS) result of <10.
- •9) The potential participant must be treated with an AChEI (i.e., donepezil, galantamine or rivastigmine) and must be on a stable therapeutic dose regimen for at least 4 months prior to the screening visit and during the entire study.
- •10) The potential participant treated with one of the following medications must be on stable doses for at least 1 month prior to the screening visit and during the entire study: anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, anticonvulsants, estrogens and statins.
- •11) The potential participant on vitamin E should not have an intake of more than 2050 IU/day for at least 1 month prior to the screening visit and during the entire study.
- •12) If the potential participant has any other clinically significant medical condition (other than AD), it has to be stable for at least 3 months prior to the screening visit.
- •13) The following screening tests must be within normal limits or determined as not clinically significant by the study physician for participant’s sex and age:
- •a. Routine 12-lead electrocardiogram (ECG),
- •b. Cranial computerized tomography (CT) or Magnetic resonance imaging (MRI) scan performed within 2 years prior to the end of the screening period and after the onset of AD symptoms.
- •c. Clinical laboratory test battery
- •14) Fluency (oral and written) in the language in which the standardized tests will be administered.
- •15) Signed informed consent from potential participant or legal representative and caregiver.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for
排除标准
- •1) Potential participants with any other cause of dementia as evidenced by medical history, general physical and neurological examination, laboratory tests, and neuro-radiological findings.
- •2) Acquired immune deficiency syndrome (AIDS) positive through medical history or HIV positive.
- •3) Allergy and/or hypersensitivity to any component of the study medication.
- •4) Life expectancy less than 2 years.
- •5) History or current evidence of seizure disorder or convulsions.
- •6) History of drug or alcohol abuse within the previous 5 years or prior prolonged history.
- •7) Current evidence or history within the past 2 years of myocardial infarction, congestive heart failure (greater than class 1 of the NYHA guidelines), cerebrovascular accident and/or transient ischemic attack.
- •8) Potential participant with a clinically significant and/or uncontrolled cardiovascular, renal, hepatic, pulmonary (including severe asthma), gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic or hematologic condition or other significant medical disease.
- •9) Presence of any clinical condition that might interfere with the interpretation of efficacy and safety results.
- •10) The presence of a significant nutritional deficiency, as assessed by the Mini Nutritional Assessment (MNA), as defined by a MNA score of less than 17.
- •11) Any condition that can significantly affect the absorption of the study medication.
- •12) ALT, ALP or AST > 2 times the upper limit of normal ranges and total bilirubin > 2 times the upper limit of normal.
- •13) Clinically significant deficiency in serum vitamin B12 or folate.
- •14) Use of memantine in the 4 months prior to the screening visit and during the course of the study.
- •15) Previous use of an investigational anti-amyloid or vaccine treatment for AD.
- •16) Participation in another drug trial within 30 days prior to the screening visit or during the study.
- •17) Potential participant has had previous exposure to Alzhemed™.
- •18) Any medical condition/device that might interfere with the performance of the MRI (MRI subset only).
- •19) Any medical condition and/or medication that might interfere with the lumbar puncture procedure (LP subset only).
- •20) Inability of participant or legal representative and caregiver to provide a signed informed consent form.
- •21) Inability to swallow medication tablets.
研究者
相似试验
进行中（未招募）
不适用
A Phase III Study of the Efficacy and Safety of Alzhemed™ as Add-on Therapy in Mild to Moderate Alzheimer's Disease Patients.EUCTR2004-003435-31-SEeurochem Inc.930
进行中（未招募）
1 期
A Phase III Study of the Efficacy and Safety of Alzhemed™ as Add-on Therapy in Mild to Moderate Alzheimer's Disease Patients.Alzheimer’s Disease (AD) is an irreversible, progressive neuro-degenartive disorder, characterized by gradual cognitive deficits associated with abnormal behaviour, personality changes, and which ultimately leads to dementia.Cerebral amyloid angiopathy (CAA) has also been found to be particularly common in Alzheimer patients.MedDRA version: 8.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseEUCTR2004-003435-31-GBeurochem Inc.930
进行中（未招募）
不适用
A Phase III Study of the Efficacy and Safety of AlzhemedTM as Add-on Therapy in Mild to Moderate Alzheimer s Disease PatientsTreatment of mild-moderate Alzheimer diseaseMedDRA version: 6.1Level: PTClassification code 10012271EUCTR2004-003435-31-ITEUROCHEM INC.
进行中（未招募）
不适用
A Phase III Study of the Efficacy and Safety of Alzhemed™ as Add-on Therapy in Mild to Moderate Alzheimer's Disease Patients.Alzheimer’s Disease (AD) is an irreversible, progressive neuro-degenartive disorder, characterized by gradual cognitive deficits associated with abnormal behaviour, personality changes, and which ultimately leads to dementia.Cerebral amyloid angiopathy (CAA) has also been found to be particularly common in Alzheimer patients.MedDRA version: 8.1Level: LLTClassification code 10001896Term: Alzheimer's diseaseEUCTR2004-003435-31-DEeurochem Inc.930
进行中（未招募）
不适用
A study of Aleglitazar in Patients with Stable Cardiovascular disease and Glucose AbnormalitiesStable Cardiovascular Disease and Diabetes Mellitus Type 2 or Pre-diabetesMedDRA version: 14.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849MedDRA version: 14.1Level: LLTClassification code 10036481Term: Pre-diabetesSystem Organ Class: 100000004861EUCTR2012-000671-16-ITF. HOFFMANN - LA ROCHE LTD.19,000